CN113365619A - 成胶质细胞瘤的治疗和预防 - Google Patents

成胶质细胞瘤的治疗和预防 Download PDF

Info

Publication number
CN113365619A
CN113365619A CN201980091073.7A CN201980091073A CN113365619A CN 113365619 A CN113365619 A CN 113365619A CN 201980091073 A CN201980091073 A CN 201980091073A CN 113365619 A CN113365619 A CN 113365619A
Authority
CN
China
Prior art keywords
adrenergic receptors
use according
selective antagonist
day
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091073.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·桑切斯-普埃勒斯冈萨雷斯-卡瓦哈尔
L·M·博特拉库贝尔斯
T·阿瓜多桑切斯
A·奎斯塔马丁内斯
V·阿尔比安娜迪亚兹
K·维拉尔戈麦斯德拉斯赫拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Federation Of Biotechnology Network Research Centers
Spanish Family Alliance For Vhl Syndrome
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Federation Of Biotechnology Network Research Centers
Spanish Family Alliance For Vhl Syndrome
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federation Of Biotechnology Network Research Centers, Spanish Family Alliance For Vhl Syndrome, Consejo Superior de Investigaciones Cientificas CSIC filed Critical Federation Of Biotechnology Network Research Centers
Publication of CN113365619A publication Critical patent/CN113365619A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980091073.7A 2018-12-12 2019-12-12 成胶质细胞瘤的治疗和预防 Pending CN113365619A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382917.5A EP3666266A1 (en) 2018-12-12 2018-12-12 Treatment and prevention of glioblastoma
EP18382917.5 2018-12-12
PCT/EP2019/084822 WO2020120656A1 (en) 2018-12-12 2019-12-12 Treatment and prevention of glioblastoma

Publications (1)

Publication Number Publication Date
CN113365619A true CN113365619A (zh) 2021-09-07

Family

ID=64746483

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091073.7A Pending CN113365619A (zh) 2018-12-12 2019-12-12 成胶质细胞瘤的治疗和预防

Country Status (7)

Country Link
US (1) US20220008362A1 (https=)
EP (2) EP3666266A1 (https=)
JP (1) JP7746157B2 (https=)
CN (1) CN113365619A (https=)
CA (1) CA3122640A1 (https=)
ES (1) ES2986469T3 (https=)
WO (1) WO2020120656A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3048032A1 (es) * 2025-05-27 2025-12-05 Univ Madrid Complutense N-(4-Ariloxi-3-hidroxibutan-2-il)alcanamidas con actividad antagonista adrenérgica beta-2 selectiva

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121500A1 (en) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of ventilator-induced diaphragmatic dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121500A1 (en) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of ventilator-induced diaphragmatic dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANDREW J. BILSKI，等: "The Pharmacology of a β2-Selective Adrenoceptor Antagonist (ICI 118, 551)", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 05, no. 03, 31 May 1983 (1983-05-31), pages 430 *
BORHANE ANNABI，等: "Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion", PHARMACOLOGICAL RESEARCH, vol. 60, no. 05, 30 November 2009 (2009-11-30), pages 1 - 3 *
KAIJUN DI ET，等: "Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier", NEURO-ONCOLOGY, vol. 18, no. 06, 17 December 2015 (2015-12-17), pages 840 - 848 *

Also Published As

Publication number Publication date
EP3893861B1 (en) 2024-08-07
JP2022517517A (ja) 2022-03-09
EP3893861C0 (en) 2024-08-07
JP7746157B2 (ja) 2025-09-30
ES2986469T3 (es) 2024-11-11
US20220008362A1 (en) 2022-01-13
CA3122640A1 (en) 2020-06-18
WO2020120656A1 (en) 2020-06-18
EP3666266A1 (en) 2020-06-17
EP3893861A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US20120128665A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
CN107106580B (zh) 治疗癌症干细胞的组合物
CN111479570A (zh) 用于治疗与dux4表达相关的疾病的化合物
JP2014503500A (ja) 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
JP7166021B2 (ja) 癌の処置のためのドーパミンβ－ヒドロキシラーゼ（ＤＢＨ）阻害剤およびセロトニン受容体（５－ＨＴ）アンタゴニストの使用
AU2016247319A1 (en) Methods for treating cancer
ES2905360T3 (es) Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
US20190231735A1 (en) Methods for treating cancer
CN106132412A (zh) 治疗癌症的新方法
WO2018138510A1 (en) Mebendazole for use in the treatment of cancer
US20190336485A1 (en) Azophenols as ERG Oncogene Inhibitors
CA2890108C (en) Method for treating prostate cancer
Lian et al. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1
CN113365619A (zh) 成胶质细胞瘤的治疗和预防
US20180098959A1 (en) Methods for treating cancer
EP2575459A1 (en) Cancer treatment with wortmannin analogs
WO2019070777A2 (en) PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS
Sánchez-Puelles et al. Treatment and prevention of glioblastoma
EP3664788B1 (en) Compounds for treating von hippel-lindau disease
Botella et al. Compounds for treating von Hippel-Lindau disease
CN121398819A (zh) 应用于治疗实体瘤中的5-htr1b调节剂
GB2554703A (en) Compound for use in medicine
EA044366B1 (ru) Соединения для лечения болезни фон гиппеля-линдау
CN120981721A (zh) Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination